Investigating targeted radiotherapy for children with neuroblastoma
Official title: Research Project 2: Neuroblastoma
Funded at Dana-Farber Cancer Inst · NIH-10931440 · Data updated 2026-11-12
This study is looking at how a special treatment called 131I-MIBG works on tumor cells in children with high-risk neuroblastoma, and it aims to find out what makes these tumors respond to the treatment and how it might affect kids in the long run, all to help improve future care for young patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $268,579 |
| NIH project number | 5U54CA274516-02 |
| Project ID | NIH-10931440 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children aged 0-11 years diagnosed with high-risk neuroblastoma.
✕Less likely to help
Patients with neuroblastoma who are not classified as high-risk or those outside the age range may not benefit from this research.
What this research studies
This research focuses on understanding how targeted radiopharmaceuticals, specifically 131I-MIBG, affect tumor cells and their environment in children with high-risk neuroblastoma. By analyzing tumor samples and blood from patients, the study aims to identify genetic and biological factors that influence how these tumors respond to treatment. The research will also explore the long-term effects of this therapy on young patients, providing insights that could improve future treatments and patient care.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for neuroblastoma and better management of late effects in pediatric patients.
How similar studies have gone: Previous research has shown promise in using targeted radiopharmaceuticals for treating various cancers, indicating potential success for this approach in neuroblastoma.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Chowdhury, Dipanjan — Dana-Farber Cancer Inst
- Study coordinator: Chowdhury, Dipanjan
Related research
Other NIH-funded projects on the same topics.
-
Computational and functional screens to find actionable neuroblastoma drivers
Researchers are using advanced computer analysis and lab tests to find new genes and drug targets in neuroblastoma, aiming to improve outcomes for children.
-
Understanding ATRX in neuroblastoma: new protein functions and treatment clues
A short, patient-friendly look at a study exploring how altered ATRX proteins in neuroblastoma might influence disease behavior and response to therapy.
-
Neuroblastoma and radiopharmaceuticals: understanding how targeted radiation affects kids’ tumors
A pediatric cancer grant studies how a targeted radiotherapy called 131I-MIBG affects tumor and surrounding cells in children with high-risk neuroblastoma.
-
Bispecific antibodies to help kids fight neuroblastoma and brain tumors
A pediatric-focused grant tests new bispecific antibodies that help the immune system attack childhood cancers like neuroblastoma and brain tumors.
-
ADEPT-STAR therapy for high risk neuroblastoma
A new cell-based therapy approach aims to help children with high-risk neuroblastoma by using off-the-shelf, donor-derived treatments.
-
MYCN and ferroptosis: a new vulnerability in pediatric neuroblastoma
A study in children with neuroblastoma looks at a new vulnerability called ferroptosis that could be exploited to more effectively treat tumors with the MYCN gene amplification.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.